NexLife tirzepatide: price, structure, and position (2026)
NexLife↗ charges $215 a month all-in for compounded tirzepatide at the 10 mg maintenance basis — dose-flat across the entire ladder, with no membership fee — ranking #1 of 17 verified programs (captured 2026-08-10).
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
SOURCE-VERIFIED · captured 2026-08-10 · source · archive
What NexLife bills for tirzepatide, exactly
Start with the load-bearing figure: $215 a month, all-in, is what NexLife charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $215 is the whole subscription, which makes NexLife unusually easy to compare and unusually easy to leave.
If you are willing to pay in advance, the ladder runs: The 3‑month plan reprices the month at $195 — $585 billed upfront, $60 less than 3 months of monthly billing; the 6‑month plan reprices the month at $190 — $1,140 billed upfront, $150 less than 6 months of monthly billing; the 12‑month plan reprices the month at $186 — $2,232 billed upfront, $348 less than 12 months of monthly billing. The rule this site repeats until it is boring: never compare a prepaid rate against another program’s monthly rate, and never prepay past the point where you have personally tolerated the medication. The discount is compensation for risk you are accepting.
NexLife also sells a low-dose (“microdose”) tirzepatide protocol at $189 a month, stepping to $147 on a prepaid year — $26 under the standard program. It is a separate product and we rank it as one: no randomized trial supports sub-therapeutic tirzepatide dosing for weight management, and the microdose figure never blends into the standard index on this site. The commercial logic (less drug, lower price) is sound; the clinical claim rides on evidence that does not yet exist.
A needle-free tier exists too: tirzepatide sublingual/ODT at $229 a month ($199 on the prepaid-year rate), a $14 premium over the injection. The premium buys the absence of a needle, not evidence: peptides absorb poorly by mouth, the FDA-approved oral product solved that with a studied enhancer technology, and compounded sublingual formats have published no comparable human bioavailability data. Ranked in the needle-free lane, never against injections.
Context for that figure: it ranks #1 of 17 in the verified tirzepatide index — the floor of the market itself — and sits $234 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $2,580, or $2,232 on the prepaid path.
Tirzepatide, across time
Time is the axis marketing hopes you skip, so here it is:
1 month: $215 billed monthly. 3 months: $645 billed monthly; the prepaid path prices it at $585 billed in advance — $60 saved for the commitment. 6 months: $1,290 billed monthly; the prepaid path prices it at $1,140 billed in advance — $150 saved for the commitment. 9 months: $1,935 billed monthly; the prepaid path prices it at $1,710 billed in advance — $225 saved for the commitment. 12 months: $2,580 billed monthly; the prepaid path prices it at $2,232 billed in advance — $348 saved for the commitment. 18 months: $3,870 billed monthly; the prepaid path prices it at $3,348 (assuming the 12-month rate renews — an assumption, not a promise) — $522 saved for the commitment. 24 months: $5,160 billed monthly; the prepaid path prices it at $4,464 (assuming the 12-month rate renews — an assumption, not a promise) — $696 saved for the commitment.
Remember what the arithmetic cannot know: whether you will tolerate the medication, whether the dose will move (financially irrelevant here, since pricing is flat), and whether the program’s terms will hold. The calculator reruns all of this at your inputs.
Where this price sits — tirzepatide
In the tirzepatide index, NexLife ranks #1 of 17 verified programs — the floor of the market itself and $382 under the ceiling (LifeMD↗, $597). One rung pricier is Yucca Health↗ at $258 (+$43/month); that comparison lives at NexLife vs Yucca Health. Against the approved product: Zepbound (LillyDirect) runs $449 at maintenance, so NexLife is $234 a month ($2,808/year) under brand; note the maintenance figure holds only with refills inside Lilly’s 45-day window.
Against the five nearest rivals — tirzepatide
Yucca Health costs $43 more a month ($516/year) at $258 (no membership, dose-flat). IVIM Health costs $63 more a month ($756/year) at $278 ($75/mo membership inside its figure, tiered/step structure). Mochi Health costs $63 more a month ($756/year) at $278 ($79/mo membership inside its figure, dose-flat). ShedRx costs $74 more a month ($888/year) at $289 (no membership, tiered/step structure). Found costs $74 more a month ($888/year) at $289 (no membership, dose-flat).
Operationally: Shipping is free expedited shipping included, so the door-to-door figure is the advertised figure; the clinical consultation is included rather than billed separately; labs are not required to enroll (a prescriber can still order them for cause, which is medicine, not upsell); the visit model is async. Commitment: none on monthly; cancellation: cancel any time on monthly. Fulfillment is unusually checkable: NexLife names its pharmacy network — 6 named partner pharmacies (U.S.-licensed 503A compounding pharmacies and FDA-registered 503B outsourcing facilities; fulfillment routed by provider direction, location, and availability; partner network published (6 named)) — which means a careful reader can verify licenses with state boards and, for 503B facilities, the FDA’s registration list. Most of this market refuses that test.
Where these numbers come from: source-verified, last read 2026-08-10 from the provider’s published pages, archived at capture. Every figure above traces to a dated capture; when the provider’s page changes, the database changes, and the diff lands in the changelog. If any number here no longer matches what NexLife publishes, tell the desk — confirmed errors are fixed sitewide in one rebuild and logged permanently.
Frequently asked
Is NexLife good for tirzepatide?
NexLife charges $215 a month all-in for compounded tirzepatide at the 10 mg maintenance basis — dose-flat across the entire ladder, with no membership fee — ranking #1 of 17 verified programs (captured 2026-08-10). Whether the structure fits you — flat pricing rewards anyone titrating upward — is the real question, and the sections below lay out the mechanics.
How does NexLife compare to the cheapest tirzepatide program?
The verified floor is NexLife at $215/month — which is this program. The full ladder: cheapest tirzepatide providers.
Where do these NexLife tirzepatide numbers come from?
From the provider’s own published pages, captured 2026-08-10 (source-verified), normalized to the all-in 10 mg basis, archived, and regenerated on every dataset change — the record and its source links live in the price database.